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SUMMARY
Hematopoietic stem cells give rise to all blood cells in
a differentiation process that involveswidespreadep-
igenome remodeling. Here we present genome-wide
reference maps of the associated DNA methylation
dynamics. We used a meta-epigenomic approach
that combines DNA methylation profiles across
many small pools of cells and performed single-cell
methylome sequencing to assess cell-to-cell hetero-
geneity. The resultingdataset identified characteristic
differences between HSCs derived from fetal liver,
cord blood, bone marrow, and peripheral blood.
We also observed lineage-specific DNA methylation
between myeloid and lymphoid progenitors, charac-
terized immature multi-lymphoid progenitors, and
detected progressive DNA methylation differences
in maturing megakaryocytes. We linked these pat-
terns to gene expression, histone modifications,
and chromatin accessibility, and we used machine
learning to derive a model of human hematopoietic
differentiation directly from DNA methylation data.
Our results contribute to abetter understandingof hu-
man hematopoietic stem cell differentiation and pro-
vide a framework for studying blood-linked diseases.
INTRODUCTION
All blood cells originate from hematopoietic stem cells (HSCs),
which represent the apex of a differentiation cascade of pro-
genitor cell types that gives rise to billions of new cells every
day. HSC differentiation is believed to progress through step-
wise restriction of lineage potential, a concept that is summa-
rized by the classical tree model of murine hematopoiesis
(Spangrude, 1991; Till and McCulloch, 1980).
HSC differentiation in human is less well understood than in
mouse. Despite recent progress (reviewed in Doulatov et al.,
2012; Theocharides et al., 2016; Vedi et al., 2016), several as-
pects of human hematopoiesis have remained controversial
(Chen et al., 2014; Doulatov et al., 2010; McCracken et al.,
2013; Notta et al., 2016; Park et al., 2008; Tanner et al., 2014;
Woolthuis and Park, 2016).
We sought to use DNA methylation for in vivo dissection
of human hematopoiesis. DNA methylation is well suited
for studying cellular differentiation because its patterns
are cell-type-specific and retain an epigenetic memory of a
cell’s developmental history. For example, cell-of-origin-specific
DNAmethylation patterns are detectable among induced plurip-
otent stem cells (Kim et al., 2011; Polo et al., 2010), and such
patterns of epigenetic tissue memory predict primary tumor
location in metastatic cancers (Fernandez et al., 2012; Moran
et al., 2016).
Previous studies have established a close connection between
stem cell differentiation and widespread epigenome remodeling.
DNA methylation has been studied in early mammalian develop-
ment (Smallwood et al., 2011; Smith et al., 2012), mouse HSC
differentiation (Bock et al., 2012; Cabezas-Wallscheid et al.,
2014; Ji et al., 2010), neural differentiation (Lister et al., 2013),
pluripotent stem cells (Bock et al., 2011; Habibi et al., 2013),
and a broad collection of human tissue samples (Kundaje et al.,
2015; Ziller et al., 2013). Chromatin accessibility has been map-
ped using the assay for transposase-accessible chromatin with
high throughput sequencing (ATAC-seq) in multiple cell types of
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Figure 1. Charting the DNA Methylation Landscape of Human Hematopoietic Differentiation
(A) Conceptual outline of human hematopoietic differentiation, highlighting the 17 hematopoietic cell types whose genome-wide DNA methylation patterns were
profiled in this study. Arrows denote established differentiation trajectories, dashed arrows indicate uncertainty about the in vivo differentiation potential of
lymphoid progenitors, and the inset illustrates the sorting of four subsets of immature multi-lymphoid progenitors.
(B) Fluorescence-activated cell sorting panel used to purify 10 stem and progenitor cell types from peripheral blood.
(legend continued on next page)
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the human blood lineage (Corces et al., 2016), and three recent
studies used chromatin immunoprecipitation sequencing (ChIP-
seq) to map histone modifications in the developing mouse
embryo (Dahl et al., 2016; Liu et al., 2016; Zhang et al., 2016).
To establish a basis for epigenome-wide analysis and
data-driven modeling of the human hematopoietic lineage,
we applied our protocol for low-input and single-cell whole
genomebisulfite sequencing (Farlik et al., 2015) to 17 hematopoi-
etic cell types (Figure 1A). HSCs and multipotent progenitors
(MPPs) were sorted from fetal liver, cord blood, bone marrow,
and peripheral blood. Eight additional progenitor cell types and
six differentiated cell types were sorted from peripheral blood,
and megakaryocytes were sorted from bone marrow. For
each stem and progenitor cell type, we sequenced an average
of 32 low-input methylomes from three individuals, and we bio-
informatically integrated them into meta-epigenomic profiles
(Wijetunga et al., 2014). Additionally, we sequenced an average
of 26 single-cell methylomes for seven cell types (HSC, MPP,
common lymphoid progenitor [CLP], common myeloid progeni-
tor [CMP], immature multi-lymphoid progenitor [MLP0], granulo-
cyte macrophage progenitor [GMP], and megakaryocytes) to
assess cell-to-cell heterogeneity.
Based on this dataset, which constitutes a community
resource of the BLUEPRINT project (Adams et al., 2012) and
the International Human Epigenome Consortium (IHEC; http://
ihec-epigenomes.org), we compared DNA methylation between
HSCs derived from different sources, and we studied changes in
DNA methylation associated with commitment to the myeloid
and lymphoid lineages. We also characterized novel subpopu-
lations of immature multi-lymphoid progenitors and investigated
the DNA methylation dynamics of megakaryocytes undergoing
endomitotic replication. We linked the observed differences in
DNA methylation to changes in gene expression, histone modi-
fications, and chromatin accessibility, and we used machine
learning to infer a model of human hematopoiesis directly from
the DNA methylation data. These results highlight the power of
DNA methylation analysis for in vivo dissection of cellular
differentiation.
RESULTS
Comprehensive DNA Methylation Maps of Human
Hematopoietic Stem and Progenitor Cell Types
We established fluorescence-activated cell sorting panels for 10
hematopoietic stem and progenitor cell types that are present in
the peripheral blood of healthy individuals (Figures 1A and 1B;
Supplemental Experimental Procedures). Each cell type was
sorted from three donors to account for inter-individual hetero-
geneity. To enhance data quality for these rare cell types, we
processed many small pools of cells in parallel and combined
the results. Specifically, for each donor and cell type, we sorted
and sequenced eight pools of 10 cells, two pools of 50 cells, and
one pool of 1,000 cells (or a lower cell number where the target of
1,000 cells could not be reached).
DNA methylation libraries were generated by whole genome
bisulfite sequencing (WGBS) using the mWGBS protocol
(Farlik et al., 2015) and sequenced at low coverage to mini-
mize the number of PCR duplicates. In total, 639 DNA methyl-
ation libraries passed quality control, and 3.1 terabases of
sequencing data were produced (Table S1). DNA methylation
profiles clustered predominantly by cell type (Figure S1A),
indicating that neither technical biases arising from the
different cell numbers nor inter-individual variation between
donors had a strong influence on our investigation of cell-
type-specific DNA methylation patterns. For further analysis,
the DNA methylation profiles of all replicates of a given cell
type were computationally combined into meta-epigenomic
maps that provide consensus DNA methylation levels as well
as an initial assessment of variability within cell types and
among individuals.
The distribution of DNA methylation levels was similar across
all stem and progenitor cell types, while we observed a shift to-
ward lower levels in differentiated cells of the myeloid lineage
(Figure 1C). Genome-wide DNA methylation patterns followed
the well-established characteristics observed in mammalian
genomes (Suzuki and Bird, 2008), including high levels of DNA
methylation in most parts of the genome (as illustrated by 5-kb
tiling regions) and locally reduced levels at gene promoters
and CpG islands (Figure 1D).
To provide a robust and biologically meaningful basis for
analyzing DNA methylation differences between cell types, we
aggregated all DNAmethylation data at the genomic region level
based on the BLUEPRINT version of the Ensembl Regulatory
Build (Zerbino et al., 2015). The BLUEPRINT Regulatory Build
integrates epigenome data across many cell types into region
sets that reflect the organizing principles of the human genome,
thus facilitating the detection of meaningful DNA methylation
differences (Bock, 2012). This catalog comprises six types
of putative regulatory regions, which exhibit broadly varying
DNA methylation levels in our dataset (Figure 1E).
The BLUEPRINT Regulatory Build also provides a frame-
work for visualization (Figure 1F) and interactive analysis
(http://blueprint-methylomes.computational-epigenetics.org) of
DNA methylation at individual genomic loci. For example, two
CTCF sites and a distal element inside the KCNH2 gene (encod-
ing a key factor for erythroid development) show decreased
DNA methylation in the myeloid lineage, consistent with
increased expression levels in CMP and GMP cells (Figure S1B).
A putative enhancer of the myeloid-linked TREML1 gene dis-
plays decreased DNA methylation in HSCs, MPPs, and myeloid
(C) Violin plots and boxplots showing the distribution of DNA methylation levels in 5-kb tiling regions for hematopoietic cell types sorted from peripheral blood.
(D) Distribution of DNA methylation levels across cell types for different sets of genomic regions. Gene and promoter annotations are based on GENCODE, CpG
islands are from the UCSC Table Browser, enhancer elements are from Ensembl, and tiling regions were calculated with a custom script.
(E) Distribution of average DNA methylation levels across cell types for putative regulatory regions annotated by the Ensembl BLUEPRINT Regulatory Build.
(F) DNA methylation at putative regulatory regions for illustrative gene loci. Black bars denote the position of regions annotated by the BLUEPRINT
Regulatory Build, and dashed horizontal black lines indicate sample medians for the respective regions. Colored vertical bars connect the highest and lowest
DNA methylation levels that have been measured in any sample of the indicated cell type.
dis, distal element; prox, proximal element; TSS, transcriptional start site. See also Figure S1 and http://blueprint-methylomes.computational-epigenetics.org.
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progenitors, which correlates with increased RNA expression
levels. CTCF sites in the lymphoid-linked SUSD3 gene show
lower DNA methylation in lymphoid progenitors, reflecting high
expression in MLP0. Finally, a promoter-associated regulatory
region in the EXOC6 gene illustrates the frequently observed
case of large DNA methylation differences that occur in the
absence of detectable changes in gene expression.
DNA Methylation Distinguishes HSCs from Fetal Liver,
Cord Blood, Bone Marrow, and Peripheral Blood
HSCs are rare in peripheral blood, whereas they exist in higher
frequencies in fetal liver, cord blood, and bone marrow. HSCs
obtained from these different sources have been shown to
vary in their differentiation capacity (Notta et al., 2016), which
prompted us to search for concomitant differences in their
DNA methylation profiles. We obtained CD34+ cells from fetal
liver, cord blood, and bone marrow, and we sorted HSCs and
MPPs in the same way as for peripheral blood (Figure 2A).
DNA methylation analysis identified many more differences be-
tween peripheral blood and any of the other three sources (fetal
liver, cord blood, and bone marrow) than between any two of the
latter (Figure 2B; Table S2). Most of the genomic regions with
source-dependent differences showed lower DNA methylation
levels in HSCs and MPPs from peripheral blood, as compared
with those obtained from the other sources.
We tested the regions that were specifically hypomethylated
in peripheral blood HSCs for associations with transcription
factor binding and regulatory elements using LOLA enrichment
analysis (Sheffield and Bock, 2016). Significant overlap was
observed with binding sites of CTCF, members of the cohesin
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Figure 2. Comparison of DNA Methylation Maps for HSCs and MPPs Isolated from Four Different Sources
(A) HSCs and MPPs were sorted from the peripheral blood of three healthy donors (Figures 1A and 1B), and in addition from fetal liver (HSCs only), cord blood
(HSCs and MPPs), and bone marrow (HSCs and MPPs).
(B) Bar plots showing the numbers of differentially methylated regions in pairwise comparisons between HSCs and MPPs from different sources, based on the
BLUEPRINT Regulatory Build regions (FDR-adjusted p% 0.05, absolute differenceR 0.167 percentage points), calculated with RnBeads (Assenov et al., 2014).
(C) Region set enrichment analysis for genomic regions with lower DNA methylation in peripheral blood-derived HSCs compared with bone-marrow-derived
HSCs. Enrichment was determined using LOLA (Sheffield and Bock, 2016). Each dot represents one ChIP-seq dataset, and the horizontal dashed line corre-
sponds to a significance threshold of 0.05 on the adjusted p-value calculated by LOLA using Fisher’s exact test.
(D) Source-specific DNA methylation at the IKBKE gene locus. Reduced DNA methylation levels in peripheral blood-derived HSC at two putative regulatory
regions (BLUEPRINT Regulatory Build) is associated with detectable expression of the IKBKE gene specifically in this cell population (bar plot).
(E) Heatmap showing DNAmethylation levels for regions that have lower DNAmethylation in peripheral blood-derived HSCs than in bone-marrow-derived HSCs
and also overlap with CTCF binding sites in the LOLACore database (left). The second heatmap (right) shows the overlap of these regions with transcription factor
binding sites that a LOLA analysis of this region set identified as enriched. Rows were arranged by hierarchical clustering with complete linkage based on the
Euclidean distances between the DNA methylation profiles.
See also Figure S2 and http://blueprint-methylomes.computational-epigenetics.org.
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Figure 3. DNA Methylation Differences Associated with Myeloid-Lymphoid Lineage Commitment
(A) Scatterplot showing average DNA methylation levels for myeloid progenitors (CMP, MEP, GMP) and lymphoid progenitors (CLP, MLP0, MLP1, MLP2, MLP3)
across BLUEPRINT Regulatory Build regions (Pearson’s r = 0.97). Differentially methylated regions were identified with RnBeads (FDR-adjusted p % 0.05,
absolute differenceR 0.167 percentage points).
(legend continued on next page)
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complex (RAD21, SMC1A, SMC3), and the transcription factors
RUNX3 and ZNF143 (Figure 2C; Table S3). We detected similar
patterns for both HSCs and MPPs, whereas no such enrichment
could be found, for example, for regions differentially methylated
between MPPs in bone marrow and cord blood (Figure S2B).
An illustrative example of peripheral blood hypomethylation of
CTCF binding sites is given by the IKBKE gene (Figure 2D), which
encodes a key kinase for NF-kB activation.
To identify additional transcription factors that may be associ-
ated with this CTCF-linked difference in DNA methylation, we
performed LOLA analysis on all regions with lower DNA methyl-
ation in HSCs from peripheral blood than from bone marrow that
also overlapped CTCF-bound regions (Figure 2E). This analysis
confirmed the strong enrichment of cohesin complex proteins,
while also detecting significant overlap for transcriptions factors
relevant for hematopoietic development (FOXA1, GATA3,MAFK)
and immune cell function (ARID3A, CEBPB, RFX5).
Myeloid-Lymphoid Lineage Choice Is Marked by DNA
Methylation Depletion at Key Transcription Factor
Binding Sites
After the initial transition from HSC to MPP, one major step of
hematopoietic differentiation is the commitment to either the
myeloid or the lymphoid lineage. DNA methylation levels at reg-
ulatory regions were on average lower in myeloid progenitors
(CMP, megakaryocyte erythrocyte progenitor [MEP], GMP)
than in lymphoid progenitors (MLP0, MLP1, MLP2, MLP3,
CLP), and the same was true for differentiated cells of the
two lineages (Figure S3A). Focusing again on the BLUEPRINT
Regulatory Build (Figure 3A; Table S2), we also identified many
more genomic regions with lower DNA methylation in myeloid
cells (n = 607) than in lymphoid cells (n = 101). On average, these
regions retained their differential DNA methylation in differenti-
ated cells of the two lineages (Figure 3B).
Differentially methylated regions between myeloid and
lymphoid progenitors were enriched for binding sites of 11 tran-
scription factors and for RNA polymerase II binding in hemato-
poietic cells (Figure 3C; Table S3). The most striking overlap
was observed between regions with lower DNA methylation in
myeloid cells and binding sites of myeloerythroid transcription
factors such as GATA1 and TAL1. In contrast, regions with lower
DNA methylation levels in lymphoid progenitors did not show
such strong enrichment patterns for any transcription factor
binding sites annotated in the LOLACore database. The average
DNA methylation levels across all binding sites of the myeloid-
specific transcription factors were reduced in myeloid progeni-
tors when compared with lymphoid progenitors (Figures 3D
and S3B). For about half of the transcription factors, the lower
DNA methylation in myeloid (as opposed to lymphoid) progeni-
tors was mirrored in higher expression levels in myeloid progen-
itors (Figure S3B).
The average DNA methylation depletion at the enriched tran-
scription factor binding sites enabled consistent grouping of
the individual replicates (10-, 50-, and 1,000-cell pools) accord-
ing to their cellular lineage (Figure 3E), whereas the segregation
by lineage was less clear when we performed the same analysis
on all transcription factors in the LOLA Core database (Fig-
ure S3C). The first five principal components calculated from
the mean-adjusted DNA methylation at the enriched transcrip-
tion factor binding sites accounted for 82.3% of the observed
variation (Figure S3D), whereas this value was much lower
when focusing on all transcription factor binding sites (63.4%)
or on all regions in the LOLA Core database (29.6%).
Averaging across pre-defined regulatory region sets is also a
powerful method for analyzing single-cell data (Bock et al.,
2016a; Farlik et al., 2015), and we applied this method to our
set of 122 single-cell DNA methylation profiles comprising
HSCs and MPPs, two myeloid progenitors (CMP and GMP),
and two lymphoid progenitors (MLP0 and CLP). Plotting all
single-cell profiles based on their mean-adjusted DNA methyl-
ation at enriched transcription factor binding sites (Figure 3F),
we observed that region sets with low levels of DNA methylation
in myeloid progenitors had much higher levels in HSCs. About
half of these region sets were highly methylated in lymphoid pro-
genitors, whereas the other half showed low levels of DNA
methylation in some lymphoid progenitors (MLP0).
Finally, we investigated how the source-specific differences
in DNA methylation among HSCs and MPPs (Figure 2) relate to
differences between the myeloid and lymphoid lineage. To this
end, we projected the DNA methylation data for HSCs and
MPPs onto the first principal component identified in our analysis
of mean-adjusted DNA methylation at transcription factor
binding sites (Figure 3E), and we plotted the distribution along
the first principal component, which was most informative for
(B) Average DNA methylation in each cell type relative to the mean over all samples aggregated over all regions with lower DNA methylation in lymphoid pro-
genitors (top) and myeloid progenitors (bottom). Error bars correspond to the standard error.
(C) Region set enrichment analysis for regions with lower DNA methylation in lymphoid progenitors (left) or myeloid progenitors (right). Enrichment was deter-
mined using LOLA. Colored dots represent ChIP-seq experiments for transcription factors in the indicated lineage. Dot size denotes the log-odds ratio, and
the numbers in the legend (‘‘X/Y’’) refer to significantly enriched region sets (X) versus all analyzed region sets (Y). The horizontal dashed line represents the
significance threshold (adjusted p% 0.05).
(D) Mean-adjusted DNAmethylation relative to the average CpGmethylation levels for each individual 10-, 50-, and 1,000-cell sample averaged across ChIP-seq
peaks for GATA1 (left) and TAL1 (right). ***p% 0.001 (two-tailed Wilcoxon test).
(E) Two-dimensional projection of all 10-, 50-, and 1,000-cell samples from peripheral blood using principal component analysis based on the mean-adjusted
DNA methylation across all transcription factor binding datasets identified by LOLA. The first two principal components are shown, and the numbers in pa-
rentheses indicate the percentage of variance explained.
(F) Heatmap displaying mean-adjusted DNA methylation for all single-cell DNA methylation profiles across the same region sets as in (E). Rows and columns are
arranged by hierarchical clusteringwith Euclidean distance and complete linkage. The labels on the right summarize the transcription factors and cell types for the
major branches of the row dendrogram.
(G) Distribution of HSC (top) and MPP (bottom) samples derived from fetal liver (FL), cord blood (CB), bone marrow (BM), and peripheral blood (PB) when
projected onto the first principal component from (E).
p.p., percentage points. See also Figure S3 and http://blueprint-methylomes.computational-epigenetics.org.
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the myeloid-lymphoid separation (Figure 3G). DNA methylation
patterns in HSCs and MPPs from peripheral blood and cord
blood were more similar to those of lymphoid progenitors,
whereas cells from bone marrow and fetal liver showed higher
similarity to myeloid progenitors.
Immature Multi-lymphoid Progenitors Show
Characteristic DNA Methylation and Distinct
Differentiation Propensities
Recent research identified a population of immature multi-
lymphoid progenitors (MLPs) that may be ancestral to CLPs in
the differentiation hierarchy (Doulatov et al., 2010, 2012; Goar-
don et al., 2011; Kohn et al., 2012). We sorted MLPs using the
published set of surface markers (Doulatov et al., 2010) and
further subdivided this cell population into four subtypes based
on their CD10 and CD7 levels (Figures 4A and S4A).
To put the MLP subtypes into context with their differentiated
progeny, we performed an unsupervised principal component
analysis based on DNA methylation for all region sets contained
in the LOLA Core database (Figure 4B). The first principal
component segregated the MLP0 population (CD10, CD7)
from the other progenitors and differentiated cell types. The sec-
ond principal component discriminated between differentiated
cell types of the myeloid and lymphoid lineage, placing the four
MLP populations in an intermediate position.
We identified the region sets in the LOLA Core database that
were most strongly associated with the first two principal com-
ponents (Figure 4C). The first principal component comprised
binding sites of broadly active transcription regulators and chro-
matin proteins (EP300, HDAC1, POL2, RBBP5, TAF1), whereas
the second principal component included binding sites of tran-
scription factors that are important for lymphoid and myeloid
cell function (FOXA1, KAP1/TRIM28, MYC, STAT1, STAT3,
TCF12).
We also assessed the differentiation capability of the lymphoid
progenitors using in vitro colony formation assays (Figures 4D
and S4B). CLPs from peripheral blood gave rise not only
to lymphoid-restricted colonies, but also to a small number of
myeloid and mixed myeloid and lymphoid colonies. This is in
contrast with a previous analysis of cord-blood-derived cells
(Doulatov et al., 2010) and highlights that the differentiation
potential of progenitor populations in human is dependent on
the cell source and stage of ontogeny (Notta et al., 2016). All
MLP populations displayed higher proportions of mixed myeloid
and lymphoid colonies than observed for the CLPs. The differen-
tiation potential was similar among the four MLP subtypes,
although MLP0 gave rise to the smallest number of myeloid-
only colonies (Figure 4D) and had the highest potential for B cells
and granulocytes (Figure 4E).
Endomitotic Replication of Megakaryocytes Is
Accompanied by Progressive Changes in DNA
Methylation Patterns
In the myeloid lineage, megakaryocyte maturation involves
endomitotic replication and an exponential increase in cell ploidy
(Figure 5A). Megakaryocytes are thought to be derived from
MEPs, although evidence for mouse and human suggests an
alternative origin directly from HSCs (Haas et al., 2015; Notta
et al., 2016; Sanjuan-Pla et al., 2013). We collected mega-
karyocytes from the bone marrow of three donors, sorted them
according to their ploidy (2N, 4N, 8N, 16N, 32N), and performed
DNA methylome sequencing on 61 single cells and ten 5-cell
pools (Table S1). The results were highly consistent between
the single-cell and 5-cell samples (Figures S5A and S5B),
arguing against technical biases caused by different DNA
amounts influencing our analysis.
Comparing DNA methylation for all LOLA Core region sets
between diploid (2N) and polyploid (32N) megakaryocytes, we
observed strong correlation (Pearson’s r = 0.99) and highly
similar distributions of DNA methylation values (Figures 5B,
S5A, and S5B), indicating that megakaryocyte maturation does
not involve any large genome-wide changes in DNA methylation
as previously observed for mouse erythroblast maturation
(Shearstone et al., 2011). Nevertheless, a small number of region
sets were differentially methylated, and these regions underwent
consistent and progressive changes across the different ploidy
stages of megakaryocyte maturation (Figure 5C).
Progressively increasingDNAmethylation levelswereobserved
for DNase I hypersensitive sites specific to hematopoietic cells
and for binding sites of NFE2, which is a regulator of megakaryo-
cyte maturation and platelet production (Lecine et al., 1998).
Conversely, decreasing DNA methylation occurred in DNase I
hypersensitive sites from a broader set of cell types and at
the binding sites of hematopoietic transcription factors with an
established role in megakaryocyte-erythroblast differentiation,
including GATA1, SMAD1, and TAL1 (Tijssen et al., 2011).
The region sets that showed progressively decreasing DNA
methylation levels in maturing megakaryocytes were on average
more highly methylated in other progenitor cell types than
in megakaryocytes (Figure S5C). In contrast, region sets with
progressively increasing DNA methylation levels during mega-
karyocyte maturation moved toward the average levels in
other progenitors rather than away from it.
DNA Methylation Differences Are Linked to Cell-type-
Specific Transcription Levels and Chromatin Signatures
DNA methylation at gene promoters can be associated with
transcriptional repression, although the genome-wide corre-
lation between DNA methylation and gene expression is
low (Jones, 2012; Suzuki and Bird, 2008). To investigate this
association in our dataset, we generated RNA-seq data
for 100-cell pools of stem and progenitor cell types sorted
from peripheral blood (Table S1) (http://blueprint-methylomes.
computational-epigenetics.org), and we identified 656 genes
thatwere differentially expressedbetweenmyeloid and lymphoid
progenitors (false discovery rate [FDR]-adjusted p % 0.05,
jlog2FCj R 1). Gene Ontology analysis revealed an enrichment
for genes associated with lymphocyte function in lymphoid
progenitors and for genes associated with hemostasis in
myeloid progenitors (Figures 6A and 6B).
When we linked the observed differences in gene expression
to DNA methylation differences at associated promoters, we
found only a small number of genes with strong and concordant
changes (Figure 6C), which is consistent with previous observa-
tions for mouse hematopoiesis (Bock et al., 2012). Among the
genes whose promoters were less methylated and more highly
expressed in myeloid progenitors were myeloid regulators
such as TAL1, MYB, MARCKS, and ICAM4. Conversely, several
814 Cell Stem Cell 19, 808–822, December 1, 2016
genes that play a role in lymphocyte function—including ITGAL,
DUSP1, and MX1—were less methylated and more highly ex-
pressed in lymphoid progenitors (Figure 6C).
We also investigated the link between DNA methylation and
histone modifications. Using ChIP-seq profiles for differentiated
blood cells types, which have been generated as part of the
A
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Erythrocytic leukemia cell PHF8
Figure 4. Characterization of MLP Populations by DNA Methylation and In Vitro Differentiation Assays
(A) Sorting panel for purifying four MLP populations from peripheral blood.
(B) Two-dimensional projection of all 10-, 50-, and 1,000-cell MLP samples using principal component analysis based on the mean-adjusted DNA methylation
relative to the average CpG methylation levels across all region sets in the LOLA Core database. The first two principal components are shown, the numbers in
parentheses indicate the percentage of variance explained, and the density plots (top and right) summarize the distribution of cell types along the two principal
components.
(C) Heatmap displaying themean-adjusted DNAmethylation for all MLP samples across the 23 25 genomic region sets that contributedmost strongly to the first
principal component (PC1, top) and the second principal component (PC2, bottom). Rows and columns are arranged by hierarchical clustering with Euclidean
distance and complete linkage. The row labels indicate the cell type and ChIP-seq target of the corresponding LOLA region sets.
(D) Differentiation potential of CLPs and four MLP populations measured by in vitro culture of single cells on MS-5 stromawith cytokines promoting lymphoid and
myeloid differentiation. The percentage of colonies that show lymphoid (CD19+ or CD56+) as well as myeloid (CD14+ or CD15+) markers was determined by flow
cytometry.
(E) Differentiation potential of theMLP populations measured as the percentage of colonies containing B cells (CD19+), granulocytes (CD15+), or NK cells (CD56+)
in flow cytometry. *p% 0.05 (Fisher’s exact test).
See also Figure S4 and http://blueprint-methylomes.computational-epigenetics.org.
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BLUEPRINT project (Adams et al., 2012), we calculated con-
sensus maps for three histone modifications (H3K4me1,
H3K27ac, and H3K27me3) in myeloid and lymphoid cells.
Regions with lower DNA methylation levels in myeloid progeni-
tors showed higher H3K4me1 levels in differentiated myeloid
cells, and the opposite was true for regions with lower DNA
methylation in lymphoid progenitors (Figure 6D). For H3K27ac,
we observed consistently higher levels in lymphoid cells
than in myeloid cells, whereas the observed differences for
H3K27me3 were less pronounced than for the other marks.
Finally, we compared our DNAmethylation datawith a recently
published chromatin accessibility dataset (Corces et al., 2016).
This dataset includes ATAC-seq profiles for several hematopoi-
etic stem and progenitor cell types, from which we derived cell-
type-specific regions of open chromatin. Genomic regions with
HSC-specific open chromatin had low DNA methylation levels
across all cell types (Figures 6E–6G, S6A, and S6B), regions
with open chromatin in differentiated cells showed reduced
DNA methylation levels only in the corresponding cell type while
being highly methylated in progenitors, and regions with acces-
sible chromatin in myeloid or lymphoid progenitors were hypo-
methylated only in differentiated cells of the respective lineage.
Computational Modeling Identifies Predictive
Epigenetic Signatures that Support Data-Driven
Lineage Reconstruction
Having identified characteristic DNA methylation dynamics in
several branches of the human hematopoietic lineage, we em-
ployed machine learning methods in order to predict cell types
from DNA methylation patterns, to quantify epigenetic similarity,
and to infer cellular differentiation landscapes. We based this
analysis on classifiers that were trained to predict cell type
from genome-wide DNA methylation profiles in putative regula-
tory regions (Figure 7A).
Specifically, we used elastic net-regularized general linear
models (Friedman et al., 2010) for predicting the cell type of
each individual stem and progenitor sample in our dataset.
These classifiers were trained on the DNA methylation levels
of all BLUEPRINT Regulatory Build regions in each 10-, 50-,
and 1,000-cell sample, and the model performance was evalu-
ated using 10-fold cross-validation (Figures 7B and S7A).
We observed high prediction accuracies for all cell types, with
receiver operating characteristic (ROC) area under curve (AUC)
values for individual cell types ranging from 0.85 to 1.00 (Fig-
ure S7A). Highest accuracies were obtained for myeloid progen-
itors (CMP, GMP, and MEP) and for the MLP0 population.
Lymphoid progenitors (CLP, MLP1, MLP2, and MLP3) were
more difficult to distinguish, consistent with their similar
DNA methylation profiles (Figure S1A) and similar functional
properties (Figure 4E). Lowest AUC values were observed for
the HSC and MLP2 cell populations, which were frequently
confused with MPPs and CLPs, respectively (Figure 7B).
The regularized classifiers weigh all genomic regions by
their discriminatory power, thus establishing a measure of their
importance for cell-type prediction. Based on this measure, we
identified a set of 1,234 signature regions whose DNA methyl-
ation levels collectively distinguished hematopoietic cell types
with high accuracy and robustness (Figure 7C; Table S4). Indi-
vidual DNA methylation differences were small for most of these
regions, highlighting that many weak but complementary differ-
ences can support accurate cell-type prediction.
LOLA enrichment analysis for the signature regions identified
significant overlap with the binding sites of key hematopoietic
transcription factors such as FLI1, GATA1/2, MYB, RUNX1,
and TAL1 (Figure 7D). Unsupervised analysis based on the
signature regions identified strong separation between myeloid
and lymphoid progenitors, but no clear clustering within each
group (Figure 7E). Moreover, differentiated cell types of the
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Figure 5. DNA Methylation Analysis of
Megakaryocyte Maturation
(A) Conceptual outline of megakaryocyte devel-
opment from MEPs via a maturation phase
involving endomitotic genome replication and a
concomitant increase in ploidy.
(B) Scatterplot comparing mean-adjusted DNA
methylation (relative to the average CpG methyl-
ation level in each sample) for all region sets in the
LOLA Core database between megakaryocyte at
the 2N and at the 32N stage of ploidy. Region sets
that were significantly less methylated in 32N
(n = 14, bottom right) or in 2Nmegakaryocyte (n = 6,
top left) are highlighted with filled circles (p% 0.05,
Wilcoxon test, absolute differenceR 10 p.p.). Point
colors indicate the magnitude of difference, and
the size is proportional to statistical significance
[log10(p)].
(C) Mean-adjusted DNA methylation in region sets
that gain (top) or lose DNA methylation (bottom) as
identified in (B), plotted across ploidy stages of
megakaryocyte maturation. Error bars correspond
to the standard error.
p.p., percentage points. See also Figure S5
and http://blueprint-methylomes.computational-
epigenetics.org.
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myeloid and lymphoid lineage formed separate clusters in the
vicinity of their corresponding progenitors.
To quantify the similarity between cell types, we trained 10
additional classifiers, each excluding one of the stem and pro-
genitor cell types (‘‘leave-one-out-classifiers’’), and we calcu-
lated the class probabilities for the samples that were withheld
from the analysis (see Experimental Procedures). These class
probabilities (Figure S7B; Table S5) define a data-driven network
model of the human hematopoietic lineage, which emerges from
the characteristic DNAmethylation patterns of each cell type and
their relationship with each other (Figure 7F).
DISCUSSION
We established genome-wide maps of the DNA methylation dy-
namics in human hematopoietic differentiation, which comprise
17 cell types, four different sources of HSCs, and a total of 639
DNAmethylation profiles. This resource, accessible via public re-
positories and a dedicated website (http://blueprint-methylomes.
computational-epigenetics.org), provides insights into the role of
epigenetic regulation in HSCs and their differentiating progeny,
and it constitutes a reference for biomedical research focusing
on diseases of the blood.
A key outcome of our study is the high accuracy with which
DNA methylation profiles predict cell type throughout the
human hematopoietic lineage. This is not merely due to the cor-
relation between DNA methylation and gene expression (which
was low in our dataset), but rather suggests that DNA methyl-
ation itself reflects a cell’s differentiation trajectory at the
epigenetic level. We showed that prediction based on DNA
methylation in regulatory regions can place sorted cell popula-
tions into a developmental context. DNA methylation analysis
thus complements studies of human hematopoietic differentia-
tion that were based on gene expression profiling (Chen et al.,
2014; Notta et al., 2016; Novershtern et al., 2011) and chro-
matin accessibility mapping (Corces et al., 2016).
To illustrate the value of our dataset for biological hypothesis
generation and for guiding mechanistic studies on specific as-
pects of hematopoietic differentiation, we focused on four areas
of the human hematopoietic lineage.
First, we compared HSCs from four different sources. Periph-
eral blood is readily accessible and therefore highly relevant for
clinical diagnostics. To establish a broadly useful reference, we
thus based most of our dataset on stem and progenitor cell pop-
ulations purified from the peripheral blood of healthy donors.
Nevertheless, the microenvironment of peripheral blood differs
markedly from that of bone marrow, cord blood, and fetal liver,
which are commonly used sources of HSCs in basic research.
HSCs from peripheral blood showed lower DNA methylation
levels at the binding sites of CTCF and cohesin complex proteins
than HSCs from other sources, which may reflect changes in
chromatin 3D architecture that influence gene expression. These
differences stress the importance of taking cell source and
microenvironment into account when studying human hemato-
poietic stem and progenitor cells.
Second, we investigated the DNA methylation dynamics of
myeloid-lymphoid lineage choice, observing an asymmetric
pattern: regulatory regions that showed reduced DNA methyl-
ation levels in myeloid progenitors were enriched for binding
sites of transcription factors associated with hematopoietic
differentiation, myeloid lineage fate, and leukemia as well as lym-
phoma, whereas there was no strong enrichment among regions
that had reduced DNA methylation levels in lymphoid progeni-
tors. This observation is consistent with DNA methylation data
for mouse hematopoiesis (Bock et al., 2012), and together with
the finding that lymphoid differentiation is compromised in trans-
genic mice with impaired maintenance DNAmethylation (Bro¨ske
et al., 2009), it supports the view that DNA methylation may
epigenetically shield lymphoid progenitors from the default
program of myeloid differentiation.
Third, we combined DNAmethylation mapping and in vitro dif-
ferentiation assays to characterize four populations of immature
multi-lymphoid progenitors that appear to constitute epigeneti-
cally and functionally distinguishable cell types. MLP0 (CD7
CD10) showed the most distinctive DNA methylation signature
and highest levels of multi-lineage differentiation potential from
individual cells. The observed patterns of multi-lineage differen-
tiation among MLPs and CLPs may reflect an underappreciated
level of epigenetic plasticity in human hematopoietic differentia-
tion (Notta et al., 2016; Paul et al., 2015).
Figure 6. Integrative Analysis of Gene Expression, Histone Modifications, and Chromatin Accessibility
(A) Heatmap showing row-normalized expression levels for 656 differentially expressed genes (FDR-adjusted p % 0.05, jlog2FCj R 1) between myeloid pro-
genitors (CMP, GMP) and lymphoid progenitors (CLP, MLP0, MLP1, MLP2, MLP3) determined using DEseq2 (Love et al., 2014). Rows and columns were
arranged by hierarchical clustering with Euclidean distance and complete linkage.
(B) Top 10 most highly enriched Gene Ontology terms associated with genes overexpressed in lymphoid (top) and myeloid (bottom) progenitors based on the
Enrichr software (Kuleshov et al., 2016).
(C) Density scatterplot contrasting myeloid-lymphoid differences in DNAmethylation at gene promoters with expression differences of the corresponding genes.
Selected genes with strong differences in DNA methylation (absolute differenceR 10 p.p.) and gene expression (jlog2FCjR 1) are highlighted.
(D) Boxplots showing histone modification levels for open chromatin-associated H3K4me1, active enhancer-linked H3K27ac, and polycomb-associated
H3K27me3 in regions that were differentially methylated betweenmyeloid and lymphoid progenitors (Figure 3A). Histonemodification levels were calculated from
multiple ChIP-seq datasets for myeloid cells (neutrophils, monocytes, and macrophages, in red) and lymphoid cells (NK cells, B cells, and CD4+/CD8+ T cells, in
blue). Brackets identify two-tailed Mann-Whitney U tests. *p% 0.05, ***p% 0.001.
(E) Heatmap showing DNA methylation levels (columns) in regions with cell-type-specific chromatin accessibility based on published ATAC-seq data for
hematopoietic cell types (rows). Numbers in parentheses denote the number of chromatin accessible regions specific to each cell type.
(F) Distribution of DNA methylation levels across regions with cell-type-specific chromatin accessibility.
(G) Composite plots showing DNA methylation averages across regions with cell-type-specific chromatin accessibility. CpGs in the neighborhood of these
regions were annotated with coordinates relative to their start and end (x axis). CpGs with a relative coordinate of 0 and 1 are located at the start and end of a
region, respectively, and the coordinates 1 and 2 correspond to one region length upstream and downstream of the region. The curves show cubic spline
smoothing of DNA methylation levels per cell type across accessible regions.
p.p., percentage points; n.s., not significant. See also Figure S6 and http://blueprint-methylomes.computational-epigenetics.org.
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Figure 7. Data-Driven Reconstruction of the Human Hematopoietic Lineage using Machine Learning
(A) Conceptual outline of the machine learning approach used to predict cell type, to identify signature regions, and to infer cellular differentiation landscapes.
(B) Confusion matrix showing the frequency of misclassification based on 10-fold cross-validation of cell-type classifiers trained and evaluated on 319 stem and
progenitor samples (all 10-, 50-, and 1,000-cell pools) from peripheral blood.
(C) Heatmap showing averageDNAmethylation levels ofmerged replicates (one column for each cell type in each donor) for the 1,234 signature regions extracted
from a classifier trained on all peripheral blood-derived stem and progenitor samples. Regions (rows) were arranged using hierarchical clustering with Euclidean
distance and complete linkage.
(D) Region set enrichment analysis for the signature regions using LOLA. Colored dots represent ChIP-seq experiments for transcription factors in the indicated
lineage. Dot size denotes the log-odds ratio, and the numbers in the legend (‘‘X/Y’’) refer to significantly enriched region sets (X) versus all analyzed region sets (Y).
The vertical dashed line represents the significance threshold (adjusted p% 0.05).
(E) Two-dimensional projection of merged replicates (one point for each cell type in each donor) using principal component analysis based on average DNA
methylation levels in the signature regions. The first two principal components are shown, and the numbers in parentheses indicate the percentage of variance
explained.
(F) Hematopoietic lineage reconstruction using the prediction propensities of DNA methylation-based classifiers as a measure of similarity between cell types.
Nodes in the graph represent cell types, and edges are weighted by class probabilities of cross-prediction. An automated edge-weighted graph layout algorithm
was used to define the positions of the nodes.
See also Figure S7 and http://blueprint-methylomes.computational-epigenetics.org.
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Fourth, we analyzed the DNA methylation dynamics over the
course of megakaryocyte maturation, which involves multiple
rounds of endomitotic replication and consequent increases in
ploidy. Whereas the cellular morphology of maturing megakar-
yocytes changes dramatically, DNAmethylation levels at regula-
tory regions showed only mild, but consistent and progressive,
changes. Certain genomic regions (counter-intuitively including
NFE2 binding sites) started off with low levels in 2N megakaryo-
cytes but gained DNA methylation up to a level comparable
with HSCs, whereas the majority of region sets started with
myeloid-like DNA methylation levels that were lost during
maturation.
In summary, we have established a comprehensive catalog of
DNA methylation in human hematopoietic differentiation, which
provides a resource and framework for studying the different
cell types of the blood, as well as their associated diseases.
Given the medical relevance (Laird, 2003) and technical feasi-
bility (Bock et al., 2016b) of using DNA methylation as a clinical
biomarker, it is expected that detailed DNA methylation analysis
of immunodeficiencies, cardiovascular diseases, and blood cell
malignancies will help advance precision medicine.
EXPERIMENTAL PROCEDURES
Sample Preparation Summary
Peripheral blood cells were isolated from apheresis filters of healthy platelet
donors belonging to the National Institute for Health Research (NIHR) Cam-
bridge BioResource after informed consent and with ethical approval (REC
12/EE/0040). Cells were stained with antibodies and sorted on either BD Influx
or BD FACSAria III fluorescence-activated cell sorting instruments. Library
preparation followed the mWGBS/scWGBS protocol as described previously
(Farlik et al., 2015). A detailed description of the sample collection, purification,
library preparation, and sequencing is provided in the Supplemental Experi-
mental Procedures.
Data Analysis Summary
Bisulfite sequencing reads were aligned with Bismark v0.12.2 (Krueger and
Andrews, 2011) and processed with RnBeads v1.5 (Assenov et al., 2014) to
aggregate DNA methylation values on regulatory regions annotated by the
August 2015 release of the BLUEPRINT Ensembl Regulatory Build (Zerbino
et al., 2015). Elastic net-regularized general linear models implemented in
the R package glmnet (Krishnapuram et al., 2005) were used for cell-type pre-
diction, and the cell-type similarity graph (Figure 7F) was derived from average
class probabilities assigned by leave-one-class-out classifiers trained sepa-
rately for each cell type. A detailed description of the sequencing data pro-
cessing, differential DNA methylation analysis, genomic region enrichment
analysis, single-cell DNA methylation analysis, and cell-type prediction is
provided in the Supplemental Experimental Procedures.
Data Availability and Accession Numbers
The presented dataset can be accessed through five alternative and comple-
mentary sources:
1. A supplemental website with additional diagrams and tables, which
also contains direct links to the other data sources, is available at
http://blueprint-methylomes.computational-epigenetics.org.
2. The genome browser track hub, which is linked at http://
blueprint-methylomes.computational-epigenetics.org, provides the
processed DNA methylation data for interactive visualization and
processing with online tools such as Galaxy.
3. Preprocessed data (DNA methylation calls and gene expression
levels) can be downloaded without any restrictions from GEO:
GSE87197.
4. The raw sequencing data from which the DNA methylation calls and
gene expression levels have been derived are available from the Euro-
peanGenome-phenome Archive (EGA): EGAS00001002070 (controlled
access to protect patient privacy).
5. The dataset is included in the epigenome registry of IHEC (http://
www.ebi.ac.uk/vg/epirr, accession numbers IHECRE00002734 to
IHECRE00002810), the DeepBlue Epigenomic Data Server (http://
deepblue.mpi-inf.mpg.de), and the IHEC Data Portal (http://
epigenomesportal.ca/ihec).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2016.10.019.
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